Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

JAK2 inhibitor TQ05105

An orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2), with potential antineoplastic activity. Upon oral administration, JAK2 inhibitor TQ05105 inhibits JAK2 activity, thereby preventing the activation of the JAK/STAT (signal transducer and activator of transcription) signaling pathway and the activation of STAT3. This may lead to an induction of tumor cell apoptosis and a decrease in tumor cell proliferation. JAK2, often upregulated or mutated in a variety of cancer cells, mediates STAT3 activation and plays a key role in tumor cell proliferation and survival.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	TQ 05105 TQ-05105 TQ05105

JAK2 inhibitor TQ05105

Search NCI's Drug Dictionary